Investor Presentaiton
36
Investor presentation
Full year 2022
Novo NordiskⓇ
The unmet need within diabetes care remains large with too few
patients reaching glycaemic target and treated for complications
1 in 2 adults go undiagnosed and more treated patients
should reach their HbA1c target
537m
35m
Prevalence Diagnosed
Treated
Reach target Treated for
complications
Prevalence
Of the 537 million, 36.3 million¹ people are currently treated with
Novo Nordisk diabetes products
6.3 mio treated with GLP-1
4.5 mio treated with
new-generation insulin
12.6 mio treated with
modern insulin
11.5 mio treated with
human insulins
Novo Nordisk products
Source: Diabetes prevalence and diagnosed are based on Diabetes Atlas 10th edition, 2021; Treated is based
on IQVIA patient data; real-world studies indicate between 30-55% of patients reach HbA₁ target <7%.e.g.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/
1 In addition to the above-mentioned product classes, oral anti-diabetics constitutes the remainder of people treated with Novo
Nordisk products; Estimated number for full-year 2022 (total available in Novo Nordisk Annual Report 2022)View entire presentation